GLEN TULLOUS: Open Payments
NPI 1720652167 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$933 in 48 payments from 18 companies in 2025. Trend: 2023 $802 · 2024 $1,138 · 2025 $933
Food & beverage: $933
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $195 |
| Novo Nordisk Inc | 5 | $108 |
| Exact Sciences Corporation | 6 | $93 |
| PFIZER INC. | 4 | $88 |
| Lilly USA, LLC | 3 | $68 |
| Otsuka America Pharmaceutical, Inc. | 2 | $58 |
| Astellas Pharma US Inc | 3 | $56 |
| AstraZeneca Pharmaceuticals LP | 2 | $40 |
| Dexcom, Inc. | 2 | $34 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $30 |
Products named: VRAYLAR, Wegovy, MOUNJARO, REXULTI, Veozah, UBRELVY, QULIPTA, The Cologuard Plus Collection Kit.
Industry payments across TX — which companies pay providers there.
